1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study
    Meeting Abstract

    Rosenberg, J. E.; Bono, P.; Kim, J.; Spiliopoulou, P.; Calvo, E.; Pillai, R.; Ott, P. A.; de Braud, F.; Morse, M.; Le, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H.; Graf, R.; Schreiber, N.; Lu, D.; Louw, J.; Alvarez, H. A. V.; Bambury, R.; Danila, D.; McLaughlin, B.; Heller, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Rosenberg, J. E.; Heath, E.; Perez, R.; Merchan, J.; Lang, J.; Ruether, D.; Petrylak, D.; Sangha, R.; Smith, D. C.; Sridhar, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
    Meeting Abstract

    Powles, T. B.; Escudier, B.; de Souza, P.; Chowdhury, S.; Pook, D.; Harmenberg, U.; Basappa, N.; Geynisman, D.; Merchan, J.; Redman, B. G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment
    Meeting Abstract

    Ray-Coquard, I. L.; Tos, A. P. D.; Coens, C.; Huizing, M.; Herraez, A. C.; Westermann, A. M.; Bompas, E.; Earl, H.; Hensley, M. L.; Negrouk, A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: Retrospective international study of invasive/advanced cancer of the urothelium (RISC)
    Meeting Abstract

    Necchi, A.; Sonpavde, G.; Lo Vullo, S.; Bamias, A.; Crabb, S. J.; Harshman, L.; Bellmunt, J.; De Giorgi, U.; Sternberg, C.; Ladoire, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase II trial investigating the highly selective c-Met inhibitor tepotinib in stage IIIB/IV lung adenocarcinoma with MET exon 14 alterations after failure of at least one prior therapy
    Meeting Abstract

    Paik, P. K.; Stammberger, U.; Bruns, R.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Rociletinib-associated cataracts in EGFR-mutant NSCLC
    Meeting Abstract

    Piotrowska, Z.; Liu, E.; Varga, A.; Thakur, M.; Narayanan, V.; Liu, S. V.; Neal, J.; Spiegel, M.; Solomon, B.; Yu, H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Meeting Abstract

    Ravaud, A.; Motzer, R. J.; Pandha, H. S.; Staehler, M.; George, D.; Pantuck, A. J.; Patel, A.; Chang, Y. H.; Escudier, B.; Donskov, F.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Ott, P. A.; Patel, M. R.; Wong, D. J.; Falchook, G.; Pant, S.; Whiteside, M.; Rasco, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save